The White House is preparing a new round of trade enforcement measures targeting two of the most strategically sensitive sectors in the global economy: semiconductors and pharmaceuticals. President Trump confirmed Tuesday that his administration will announce tariffs on imported semiconductor products and is actively considering a 200% tariff on pharmaceutical imports. These moves follow Section 232 investigations that revealed systemic vulnerabilities in both supply chains, particularly the U.S. dependence on foreign production and the exposure to retaliatory tariffs from adversarial nations.
China’s pharmaceutical retaliation peaked at 125% before collapsing to 10% following negotiations. That reversal came only after the U.S. imposed sectoral tariffs and forced Beijing to dismantle non-tariff barriers. The administration argues that the proposed 200% pharma tariff is not punitive but a necessary tool to counter foreign price manipulation and protect domestic manufacturing. Trump stated, “We’re going to give people about a year, year and a half to come in, and after that, they’re going to be tariffed at a very, very high rate, like 200%.”
The semiconductor tariff push is expected to complement S.5108, which incentivizes reshoring of chip production through targeted investment and foreign direct capital coordination. The U.S. trade deficit in semiconductors reached $322 million in January 2025, with imports totaling $843 million and exports at $521 million. Trump emphasized the need to “uncomplicate” the electronics supply chain and bring chip manufacturing back to U.S. soil.
These actions also align with H.R.10393, the Medical Supply Chain Resiliency Act, which authorizes the President to negotiate trade agreements with trusted allies to secure medical goods and services. The bill aims to reduce reliance on adversarial nations and expand domestic production capacity.
The pharmaceutical industry has warned that tariffs could disrupt supply chains and exacerbate drug shortages. However, the administration maintains that the long-term benefits of reshoring outweigh short-term disruptions. Trump’s team has signaled that final tariff decisions will be announced at the end of July, following completion of Commerce Department studies.
Sources
https://www.businesstimes.com.sg/international/trump-says-pharmaceutical-tariffs-could-reach-200
https://www.congress.gov/bill/119th-congress/house-bill/2480/text
https://www.forbes.com/sites/alisondurkee/2025/07/08/trump-floats-200-tariffs-on-pharmaceuticals/
